Phase II Study of Rituximab in Patients With Immune Thrombocytopenic Purpura

Part of paid clinical trials in Birmingham, Alabama.

Sponsor
University of Alabama at Birmingham
Study ID
NCT00005652
Phase
PHASE2
Status
Completed

Conditions

  • Purpura, Thrombocytopenic, Idiopathic

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

OBJECTIVES: I. Determine the response rate and response duration to rituximab in patients with immune thrombocytopenic purpura. II. Evaluate the toxicity associated with this treatment regimen in these patients. III. Evaluate the alteration in antiplatelet antibody with this treatment regimen in these patients.

Key Dates

Start date
Dec 31, 2000
Status verified
Sep 2008
Primary completion
Aug 31, 2007

Study Design

Enrollment
20 participants
Primary purpose
TREATMENT

Locations (1)

FacilityCityStateZIPSite coordinators
University of Alabama Comprehensive Cancer CenterBirminghamAlabama35294-

Find similar trials in Birmingham, AL

By research site
University of Alabama Comprehensive Cancer Center· Birmingham, AL